With Lilly on board, Entos' medical chief champions genetic platform with 'unlimited' potential

 Steve Chen is helping to lead Entos through an ‘inflection point’ in the development of its precision medicine delivery platform.

By Alexandra Pecci • April 14, 2022

What now? Alzheimer's drugmakers ponder the path to approval

Why Medicare’s unprecedented decision to limit coverage for Aduhelm could have a chilling effect on Alzheimer’s R&D.

By Kelly Bilodeau • April 14, 2022

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Woman of the Week: iSpecimen's Jill Mullan

Need biospecimens? iSpecimen aims to be the Amazon of research materials, and Jill Mullan is changing the game.

By Taren Grom • April 13, 2022

Why the war in Ukraine could accelerate the deglobalization of clinical trials

COVID-19 slowed many studies — but the war could further strain clinical trials worldwide.

By Michael Gibney • April 12, 2022

'Bootcamp' helps rare disease advocates learn the ropes of drug development

Ultragenyx’s CEO on why supporting others in rare diseases pays dividends all around.

By Kim Ribbink • April 12, 2022

Woman of the Week: Lyell Immunopharma's Liz Homans

The CEO has the company poised to capitalize on its moment to address T cell exhaustion.

By Taren Grom • April 6, 2022

A planned trial revives a glimmer of hope for a Huntington's disease treatment

Roche brought a Huntington’s drug back to life after a jarring trial halt.

By Kelly Bilodeau • April 6, 2022

An analyst turned pharma CEO learns the art of operations

Under Apurva Saraf’s guidance, Cosette Pharmaceuticals is pivoting wholeheartedly into the cardio space.

By Jared Whitlock • April 5, 2022

Down but not out: How AVEO's CEO steered the company past an FDA rejection

Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.

By Kim Ribbink • April 5, 2022

Clinical trial recruitment hits the local pharmacy counter

CVS Health's partnership with clinical trial software company Medable is designed to make recruitment easier for patients and drug makers alike.

By Kelly Bilodeau • April 5, 2022

Lessons from improv: Shankar Narayanan’s ‘yes, and’ approach to healthcare leadership

Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.

By Taren Grom • April 4, 2022

Sangamo has its finger on the next evolution of gene editing

Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

By Taren Grom • March 31, 2022

Rare Patient Voice's president is striving to create a five-star experience for patients

Successful clinical trial recruitment depends on listening to and empowering patients.

By Kim Ribbink • March 23, 2022

Another pandemic threat looms, and the antibacterial drug pipeline still isn't keeping up

A recent report from BIO details challenges in the antibiotic market — and new policy measures that could help.

By Kelly Bilodeau • March 23, 2022

Why Astellas is adopting a 'focus area approach' to partnerships

Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.

By Kim Ribbink • March 22, 2022

Psychedelics without the party: Inside MindMed's LSD makeover

MindMed’s CEO, Robert Barrow, on the company’s latest moves to ‘change the world’ with psychedelics.

By Alexandra Pecci • March 21, 2022

Attralus' medical officer believes systemic amyloidosis could be 'solvable'

Gregory Bell is not just aiming to treat amyloidosis, but eventually cure it.

By Robin Robinson • March 18, 2022

COVID-19 trials aren't the only studies that can achieve super speed

Is it possible to enroll clinical trials 10 times faster than the industry’s average speed? Elligo Health Research thinks so.

By Kelly Bilodeau • March 15, 2022

Medigene's CEO on striking a collaboration deal with BioNTech

The two companies recently announced a $29 million collaboration. 

By Jared Whitlock • March 15, 2022

Clearing hurdles in rare cancer drug development

Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

By Kim Ribbink • March 14, 2022

Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage

The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.

By Taren Grom • March 14, 2022

Ultragenyx's CEO on building a 'next-gen' rare disease company

How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

By Kim Ribbink • March 9, 2022

Woman of the Week: Genentech's Quita Highsmith

Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.

By Taren Grom • March 9, 2022

Horizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride

Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.

By Alexandra Pecci • March 8, 2022

Two key factors behind NYC's record-setting rise in healthcare funding

According to a new report, women’s and digital health led to an explosion in funding last year in NYC.

By Robin Robinson • March 7, 2022